Exosomes Increase the Therapeutic Index of Doxorubicin in Breast and Ovarian Cancer Mouse Models

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2016 Aug 26

PMID 27558906

Citations 119

Authors

Mohamad Hadla

Stefano Palazzolo

Giuseppe Corona

Isabella Caligiuri

Vincenzo Canzonieri

Giuseppe Toffoli

Flavio Rizzolio

Affiliations

Soon will be listed here.

Abstract

Aim: To demonstrate that exosomes (exo) could increase the therapeutic index of doxorubicin (DOX).

Materials & Methods: Exosomes were characterized by nanoparticle tracking analysis and western blot. Tissue toxicity was evaluated by histopathological analysis and drug efficacy by measuring tumor volume. DOX biodistribution was analyzed by MS.

Results: Exosomal doxorubicin (exoDOX) avoids heart toxicity by partially limiting the crossing of DOX through the myocardial endothelial cells. For this reason, mice can be treated with higher concentration of exoDOX thus increasing the efficacy of DOX as demonstrated in breast and ovarian mouse tumors.

Conclusion: ExoDOX is safer and more effective than free DOX. Importantly, the first spontaneous transformed syngeneic model of high-grade serous ovarian cancer was utilized for providing a new therapeutic opportunity.

Citing Articles

Harnessing tomato-derived small extracellular vesicles as drug delivery system for cancer therapy.

Sarwareddy K, Singh A, Patnam S, Sesuraj B, Ponamgi S, Thakur B Future Sci OA. 2025; 11(1):2461956.

PMID: 39920889 PMC: 11812386. DOI: 10.1080/20565623.2025.2461956.

Emerging roles of exosomes in diagnosis, prognosis, and therapeutic potential in ovarian cancer: a comprehensive review.

Tuscharoenporn T, Apaijai N, Charoenkwan K, Chattipakorn N, Chattipakorn S Cancer Gene Ther. 2025; 32(2):149-164.

PMID: 39843770 DOI: 10.1038/s41417-025-00871-2.

vCPP2319 interacts with metastatic breast cancer extracellular vesicles (EVs) and transposes a human blood-brain barrier model.

Oliveira F, Cavaco M, Figueira T, Napoleao P, Valle J, Neves V Heliyon. 2024; 10(23):e40907.

PMID: 39717586 PMC: 11664409. DOI: 10.1016/j.heliyon.2024.e40907.

Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.

Afkhami H, Yarahmadi A, Bostani S, Yarian N, Haddad M, Lesani S Discov Oncol. 2024; 15(1):818.

PMID: 39707033 PMC: 11662135. DOI: 10.1007/s12672-024-01590-0.

Co-culture system of breast cancer and normal cells to investigate inflammation: using doxorubicin encapsulated in adipose-derived exosomes.

Shirzad M, Daraei A, Najafzadehvarzi H, Farnoush N, Parsian H Med Oncol. 2024; 42(1):21.

PMID: 39630192 DOI: 10.1007/s12032-024-02568-2.